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Impact of temperature, energy output and impedance drop during renal
denervation on the long-termn outcome
Klaus Tiroch1, Armin Sause1, Ina Schmitz1, Jacek Szymanski1, Melchior Seyfarth2
1HELIOS Klinkum, Wuppertal, Germany, 2HelELIOS Klinikum, Wuppertal,
Germany
Background: Renal denervation (RDN) through catheter ablation is emerging as a
promising therapeutic option for refractory hypertension, but the decrease in blood
pressure (BP) is difficult to predict and is usually evident only after months. No acute
variable is available to date to predict the BP response.
Methods: This analysis is based on 23 patients with RDN performed at our institution
within the last 14 months. Complete information regarding all ablation points was present
for 18 patients (194 ablation points). 15 patients had complete 3-months follow-up
including 24-hour BP, and for 10 of these patients the complete information regarding the
ablation points was present.
Results: 20 patients had a bilateral RDN with 4,51,2 ablation points per renal artery,
2 patients only monolateral due to 40% narrowing of the other artery. One patients
experienced asystoly after ostial RDN of the first renal artery requiring CPR and
intubation. He received a pacemaker and recovered completely. 79,9% of ablation points
required the max. energy output (8W). The BP decreased from 151/77 to 134/72 mmHg
(P0.07 for syst. RR) and the percentage of patients with systolic BP 140mmHg from
57% to 31% (P0,04) on an average of 3,80,9 medications.
Conclusions: RDN can reduce hypertensive peaks. Marked suppression of sympathetic
activity can cause bradycardia and hypotension and requires alert supervision during
ablation. Impedance drop correlates highly significant with ablation temperature and
seems to correlate better with long term reduction of mean BP than ablation temperature,
suggesting an impact of impedance drop on outcome.
TCT-205
Histologic analysis of renal nerve injury following catheter-based renal
denervation in obese, hypertensive canines
Jeffrey Henegar1, Yongxing Zhang2, Rita DeRama2, Cary Hata2, John Hall1
1University of Mississippi Medical Center, Jackson, MS, 2St. Jude Medical, Inc.,
Irvine, CA
Background: Catheter-based intravascular renal denervation (RD) using radiofrequency
energy has shown promise in the treatment of resistant hypertension. However, to date, no
studies have examined the extent of renal nerve injury following RD.
Methods: To examine renal nerve injury following RD, nine obese, hypertensive dogs
underwent bilateral RD using the St. Jude Medical EnligHTN™ renal denervation system
and eight weeks of hemodynamic monitoring. At the end of the eight-week period, both
left and right renal arteries were collected from the aorta to the kidneys. The renal arteries
were cut into equal sections, fixed, and embedded in paraffin. Multiple five-micron
sections were taken from the bifurcation, main renal artery, and the ostium and stained
with hematoxylin-eosin. Sections were examined for the total number of nerves, number
of injured nerves, and the distance measured from nerves to the renal artery lumen.
Results: Renal nerves were found from 0.28 mm to 6.7 mm from the renal artery lumen.
Twelve percent of the nerves were found between 0.28mm and 1mm from the artery
lumen, fifty-seven percent between 1mm and 2.5 mm, seventeen percent between 2.5mm
and 3.5mm, and fourteen percent between 3.5mm and 6.7mm. Forty-two percent of
nerves exhibited injury due to RD (157 out of 371); however, since samples were
examined 8 weeks after RD, some injured nerves may have degenerated and become
unobservable. Injury was found at nearly all distances from the artery lumen but was most
prevalent from 0.28mm to 3.5mm. Renal nerve injury was found in thirty-six percent of
the nerves near the bifurcation, forty-one percent in the main renal artery, and fifty-six
percent near the ostium.
Conclusions: Our data show that renal nerves span a great distance from the renal artery
lumen in obese canines. These data also suggest that the RD travels approximately 3.5mm
from the artery lumen surface in obese dogs; however, renal nerve injury is noted further
out. The injury further from the luminal surface is presumably the result of Wallerian-type
degeneration. The current study showed that RD using the St. Jude Medical EnligHTN™
renal denervation system does cause significant injury to renal nerves.
TCT-206
A Pilot Study on Renal Sympathetic Denervation for Resistant Hypertension
in the West of Ireland
Imtiaz Kalyar1, James Gleeson1, Sajjad Matiullah1, Faisal Sharif1
1Galway University Hospitals, Galway, Galway
Background: Renal Sympathetic Denervation (RSD) is a novel, device-based interven-
tion for the management of resistant essential hypertension (RH). Here we present the data
from our initial experience of renal artery denervation for the first 12 patients.
Methods: All patients in this pilot study (n12) had RH, and were on a minimum of 3
medications. The effect of RSD on office blood pressure, 24 hour ambulatory blood
pressure, number of anti-hypertensive medications, renal function, weight, serum uric acid
concentration, excretory fraction of sodium, and renin-aldosterone levels was investi-
gated. We also assessed the safety of the procedure. Prior to intervention secondary causes
of hypertension were excluded, and detailed anatomy of the renal arteries was obtained
using either CT or MR angiography. Patients were followed up at 2 weeks, 2 months and
6 months for serum biochemistry, urinalysis and office BP. Ambulatory BP was assessed
pre- and 2 months post RSD.
Results: At 2 months the average decrease in office BP was 33/15mmHg (systolic p 
0.04, diastolic p0.03), while the observed reduction in 24 hour ambulatory BP readings
was 26/16mmHg (systolic p0.01, diastolic p0.01). The range in change of serum
creatinine values at 2 months was10 to	13 mol/L, and the average change was	1.5
mol/L (p0.47). There was a 6.6% reduction in mean uric acid concentration
(p0.371). A trend towards weight loss, with an average reduction in weight of 1.65kg
at 2 month follow up was seen (p 0.27). Patients required, on average, 1.3 medications
less at follow up. There have been no major complications to date.
Conclusions: RSD was safe, and effective at reducing both systolic and diastolic blood
pressure in patients with RH. No acute deterioration in renal function was demonstrated.
Findings from this pilot study showed more substantial reductions in ambulatory BP
consistent with larger studies.
TCT-207
Beta Radiation For Renal Nerve Denervation: Initial Feasibility And Safety
Ron Waksman1, Israel Barbash2, Rosanna Chan3, Pamela Randolph-Jackson2,
Richard Baffour4, Rufus Seabron5, David Hellinga6, Addisalem Makuria7,
Renu Virmani8
1Georgtown University, Washington, DC, 2Washington Hospital Center,
Washington, DC, 3Washington hospital center, Washington, DC, 4Washington
hsopital Center, Washington , DC, 5Washington hospital Center, Washington, DC,
6Washingotn hospital Center, Washington, DC, 7CVPath, Gaithersburg, MD,
8CVPath Inc, Gaithersburg, United States
Background: Sympathetic renal denervation shows promise in treating resistant hyper-
tension. The percutaneous RF ablation approach is currently undergoing evaluation but
has several limitations. Vascular brachytherapy has the potential to damage nerves. The
purpose of the present study was to assess safety and feasibility of renal artery
brachytherapy for sympathetic renal denervation.
Methods: A total of 10 normotensive domestic swine underwent vascular brachytherapy
to left and right renal arteries using the Beta-Cath™ 3.5F System with doses of 25 Gy and
50 Gy at 2 mm from the source center. Each treated group had 8 arteries; 4 untreated
arteries served as control. Follow-up obtained at 1 or 2 months included angiogram,
intravascular ultrasound, norepinephrine levels and histopathology.
Results: Overall the vascular brachytherapy procedure was safe and there were no
apparent angiographic or ultrasound injuries to the vessel. Histology demonstrated a
variable degree of thermal injury more pronounced in the 50 Gy group. The majority of
the examined nerves showed some degree of injury. (Figure) There was a dose-related
effect on the severity of the nerve injury. There was a varied degree of arteriolar changes
in the examined sections; most showed a varied degree of endothelial cell loss of
approximately 2% to 20%.
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Conclusions: This initial feasibility and safety study of renal nerve denervation mediated
by low and intermediate -radiation dosages indicates that this approach can cause
substatntial nerve damage while avoiding significant damage to the renal artery.
TCT-208
Catheter-based renal sympathetic denervation – results of the heidelberg
registry
Michael Kirchberger1, Erwin Blessing1, Hugo Katus1, Britta Vogel1, Martin Zeier1
1University of Heidelberg, Heidelberg, Germany
Background: Renal sympathetic denervation is a novel treatment option in patients with
treatment resistant hypertension. Registry data allow to evaluate safety and efficacy in a
real-world szenario.
Methods: 53 consecutive patients with treatment resistant hypertension underwent renal
sympathetic denervation with the Symplicity radiofrequency based catheter. At baseline,
mean office blood pressure was 17122/9317 mm Hg. The mean number of
antihypertensive agents was 5.0.
Results: At 6 months follow up, office systolic blood pressure improved to 15118 mm
Hg (minus 20 mm Hg compared to baseline; p0.0001), the diastolic blood pressure to
8611 mm Hg (minus 7 mm Hg compared to baseline, p0.001). The response rate,
defined as reduction of office systolic blood pressure of 10 mm Hg was 66%. In 9
Patients (17%), number of dosage of antihypertensive agents could be reduced. The mean
number of ablations points per kidney was 4.3. There was no correlation between the
number of ablation points and blood pressure response (r 0,25, pns).
Conclusions: Renal sympathetic denervation with the Simplicity systems results in a
significant reduction of office systolic and diastolic blood pressure reduction in patients
with treatment resistant hypertension. Effects on blood pressure were somewhat less
profound than reported in the Symplicity trial program, reflecting a real world szenario
with more liberal use of the method. Interestingly, there was no correlation between the
number of ablation points and blood pressure response.
TCT-209
Durable Reduction In Blood Pressure In the First Cohort of Patients Treated
With Renal Sympathetic Denervation Therapy For Resistant Hypertension
Sonny Palmer1, Michael Stokes1, Christopher Judkins1, Paul Williams1,
Robert Whitbourn1
1St Vincent’s Hospital, Melbourne, Victoria, Australia
Background: Resistant hypertension is associated with significant cardiovascular mor-
bidity and mortality and it poses a significant treatment challenge for physicians. The
treatment of resistant hypertension by renal sympathetic denervation (RD) has demon-
strated excellent short-term reductions in blood pressure (BP) at six-months as reported by
the Symplicity HTN-2 Investigators. The future role of RD is evolving and long-term
results will clarify it’s durability. Here we assess the long-term results in the first cohort
of patients to be treated with RD in Australia.
Methods: We compared the baseline office-based BP to long-term follow-up office-based
BP, number of prescribed anti-hypertensive medications, major adverse cardiac and
cerebrovascular events (MACCE) and hospital admissions in 8 patients whom had
undergone RD from July 2007 to January 2008.
Results: Our cohort had a mean follow-up of 43 months and we found that office-based
BP measurements were reduced by a mean of 30/9 mmHg when compared to baseline
measurements (p0.003 systolic; p0.09 diastolic). The mean number of prescribed
anti-hypertensive medications remained stable throughout the follow-up period (4.88
medications pre-treatment vs 4.1 medications at follow-up; pNS). Two patients required
hospitalisation for late cerebrovascular events. There were no cardiac events reported.
Conclusions: This is the longest reported follow-up of renal sympathetic denervation
patients. We have demonstrated a significant and durable decrease in blood pressure.
However, there has been no reduction in the number of prescribed anti-hypertensive
medications.
TCT-210
Decrease of the norepinephrine release from sympathetic nerves during renal
denervation
Klaus Tiroch1, Ina Schmitz1, Melchior Seyfarth2, Jacek Szymanski1
1HELIOS Klinkum, Wuppertal, Germany, 2HelELIOS Klinikum, Wuppertal,
Germany
Background: Renal denervation (RDN) is a promising new treatment option for
pronounced hypertension refractory to medical therapy. Interestingly, only 70-80% of
patients have a relevant reduction in blood pressure (BP) three to six months after RDN
when assessed by systematic 24h BP measurements. No variables have been identified to
date predicting the BP response.
Methods: We assessed 11 patients with bilateral renal denervation for the changes of pre-
and postprocedural norepinephrine (NE) and epinephrine (E) levels measured directly
from the renal artery (RA) and vein (RV). We defined the respective spillover for NE
and E as the difference RV-RA and compared this difference before and after the
procedure.
Results: We assessed NE and E for 88 probes (11 patients x 2 (bilateral probes) x 2 (RA
and RV) x 2(pre- and post-procedural)). There was a significant decrease of the NE
RV-RA spill-over comparing pre- with post-procedural levels (184pg/ml180 decrease
to 97pg/ml137, P0.03 for paired t-test). There was no significant change in the
epinephrine levels during the procedure under conscious sedation (56pg/ml192 com-
pared to 29pg/ml171, P0.62 for paired t-test). The pre-post NE RV-RA was even
more pronounced when the median values were compared (P  0.02).
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